Nobilis Therapeutics leadership will be attending J.P.Morgan’s 36th Annual Healthcare Conference that will take place in San Francisco on January 8-11. If you are interested in setting up a f2f meeting with our team, please send us an email.
News
- US Patent Granted for Nobilis Therapeutics Invention Covering the Use of Xenon in ALS August 27, 2019
- Nobilis Therapeutics will present two abstracts at the 19th WPA World Congress of Psychiatry July 17, 2019
- Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders. January 10, 2019
- Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder January 6, 2019
- Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results January 2, 2019
Recent Posts
- US Patent Granted for Nobilis Therapeutics Invention Covering the Use of Xenon in ALS
- Nobilis Therapeutics will present two abstracts at the 19th WPA World Congress of Psychiatry
- Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders.
- Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder
- Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results
Recent Comments